As per MRFR analysis, the India Cancer Immunotherapy Market Size was estimated at 3.34 (USD Billion) in 2023. The India Cancer Immunotherapy Market Industry is expected to grow from 3.51 (USD Billion) in 2024 to 6 (USD Billion) by 2035. The India Cancer Immunotherapy Market CAGR (growth rate) is expected to be around 4.995% during the forecast period (2025 - 2035).
The India Cancer Immunotherapy Market is studding due to a plethora of reasons. One significant element is the growing technological advancement in the treatment options available. As newer equipment and medicines are developed, there are higher chances of curing cancers such as lung, breast and oral, all of which are common in Indian citizens. With an increase in the prevalence of these cancer types, there is also a growing need for better treatment methods.
The collaborations that the Indian government have set to promote research regarding immunotherapy is a huge factor within the public and private combination, which also works towards cancer treatment. The policy shifts are positive as well since there is quicker approval for new therapies that need to be introduced into the welfare system. There are great chances in this market which include the creation of personalized immunotherapeutic designs that match the DNA sequences of the patients.
Studying the genetic variations among the people of India can lead to more precise treatment solutions. Moreover, the growing interest from both physicians and patients toward the advantages of cancer immunotherapy serves as a beneficial chance for market players to inform and broaden their outreach. Subsidy’s funding clinical trials is crucial to prove the effectiveness of new immunotherapy medications.
Recently, there is a marked movement toward the use of combination therapies which integrates the use of immunotherapy with standard cancer treatment such as chemotherapy and radiation. The growing emphasis toward improving treatment efficacy and the reduction of the treatment’s side effects are driving researchers toward these combinations.
In addition, the progress of technologies such as artificial intelligence and bioinformatics is helping to identify new biomarkers related to patient selection and treatment response for monitoring. These developments highlight the movement of change within India’s healthcare system with a focus on the role of immunotherapy in the cancer treatment system of the country.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The rise in cancer cases is a significant driver for the India Cancer Immunotherapy Market Industry. According to the National Cancer Registry Programme (NCRP), India has seen a 20% increase in cancer cases over the last decade, with an estimated 1.16 million new cancer patients reported in 2020 alone. This alarming statistic raises awareness and urgency for innovative treatment solutions like immunotherapy.
As healthcare providers and government bodies strive to control this increasing burden, organizations such as the Indian Council of Medical Research (ICMR) are actively promoting awareness and access to advanced treatment options. The growing population of cancer sufferers fuels a pressing demand for effective therapies, ultimately driving growth in the immunotherapy market.
Government initiatives to support cancer research and treatment are pivotal in enhancing the India Cancer Immunotherapy Market Industry. The Union Government’s National Health Mission (NHM) has increased funding for cancer control programs by approximately 30% over the past three years. This financial encouragement facilitates Research and Development (R&D) collaborations between public and private sectors.
Leading health organizations, such as the Ministry of Health and Family Welfare (MoHFW), are promoting immunotherapy as a critical component of national health priorities, thereby stimulating investment in this sector. Such policy support will continue to fuel market expansion and innovation in cancer immunotherapy.
The continuous advancements in biotechnology and cancer research are essential levers for the India Cancer Immunotherapy Market Industry. The Indian biotechnology sector is projected to grow significantly, with an expected Compound Annual Growth Rate (CAGR) of approximately 22% from 2020 to 2025, driven by innovations in genetic engineering and immunotherapy techniques.
Major institutions like the Tata Memorial Centre are engaged in state-of-the-art research, resulting in patents and clinical trials that enhance the understanding and application of immunotherapy. This evolving landscape of biotechnological advancements contributes to the wider acceptance and effectiveness of cancer immunotherapy solutions in India, aligning with both clinician and patient needs.
The India Cancer Immunotherapy Market is witnessing notable advancements in its Therapy Type segment, reflecting a crucial shift in the approach to cancer treatment across the region. Within this framework, various innovative therapies are emerging as transformative solutions for battling different types of cancer. Monoclonal antibodies represent a significant portion of the immunotherapy landscape, leveraging their ability to target specific antigens on cancer cells, leading to enhanced treatment efficacy.
The continued rise in targeted therapies, backed by increasing investments in Research and Development, positions monoclonal antibodies as a vital choice for oncologists in India. Moreover, Check Point Inhibitors are gaining traction as a ground-breaking immunotherapy option, functioning by enabling the immune system to recognize and attack cancer cells more effectively. This class of drugs has shown substantial promise in the treatment of various cancers, including lung and skin cancer, making them instrumental in improving patient outcomes.
As healthcare facilities in India increasingly adopt innovative treatment modalities, Check Point Inhibitors stand out due to their ability to deliver lasting immune responses. Cancer Vaccines, another prominent category, are being explored vigorously for their potential to stimulate the immune system against malignancies. With a focus on developing early-stage vaccines and personalized treatments, India is making strides in offering patients vaccines that can prevent or treat cancers more efficiently.
The growing awareness around preventive healthcare is driving interest in such vaccines among the population, further indicating a paradigm shift in cancer treatment strategies. Therapeutic T-Cells are also emerging as a critical entity within the immunotherapy spectrum, utilizing modified T-cells to target and destroy cancer cells. This innovative approach reflects the potential for individualized treatment plans that harness the patient’s immune system, directly addressing the tumor cells while minimizing damage to healthy tissues.
As the Indian population becomes more informed about immunotherapeutic options, the demand for therapeutic T-cells is likely to enhance significantly. Oncolytic Virus Therapy presents a cutting-edge avenue in the India Cancer Immunotherapy Market, where naturally occurring or genetically engineered viruses selectively replicate within and kill cancer cells while sparing normal cells. This dual-action creates a compelling option for patients, combining direct tumor destruction with the activation of systemic anti-tumor immunity.
The exploration of oncolytic viruses reflects a broader trend towards seeking innovative methods to integrate conventional and alternative cancer treatments under a holistic umbrella. Overall, the variety within the Therapy Type segment encapsulates both the advancements in oncology and the emerging patient-centric approaches in India. The continued exploration and application of these therapies are expected to revolutionize cancer treatment in the region, with Indian research institutions and pharmaceutical companies actively contributing to the development and validation of these essential modern treatment modalities.
With the support of government initiatives and an increasing network of clinical trials, the encompassing range of therapies stands poised to address the burgeoning cancer burden in India effectively.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The India Cancer Immunotherapy Market exhibits a diverse segmentation based on Cancer Type, highlighting various prevalent cancers in the region. Breast Cancer remains a prominent focus, largely due to its high incidence rates among women, making advancements in immunotherapy crucial for improving patient outcomes. Lung Cancer is also significant, with rising smoking rates and air pollution contributing to its prevalence, thus necessitating innovative treatment approaches through immunotherapy.
Colorectal Cancer poses a growing challenge, driven by dietary habits and lifestyle changes, which calls for effective immunotherapeutic interventions to enhance survival rates. Prostate Cancer, being one of the most common cancers among men, emphasizes the need for targeted therapies that leverage the immune system to combat this disease. Melanoma, while less common, has been gaining attention due to its increasing incidence, particularly in urban populations, highlighting the potential of immunotherapies in addressing aggressive forms of skin cancer.
The segmentation within the India Cancer Immunotherapy Market reflects the importance of tailored treatment options driven by prevalent cancer types, ultimately aiming to improve patient care and therapeutic efficacy amidst ongoing challenges in the healthcare landscape.
The India Cancer Immunotherapy Market is witnessing a notable presence of various End User categories, primarily dominated by Hospitals, Cancer Research Institutes, and Diagnostics Labs. Hospitals play a crucial role, as they are often the primary point of contact for patients seeking cancer treatment, providing comprehensive care facilities and advanced immunotherapeutic options.
Cancer Research Institutes are essential for driving innovation and discovering new therapies, playing a pivotal role in clinical trials and the development of novel immunotherapeutic agents. Meanwhile, Diagnostics Labs are integral in accurately diagnosing cancer types and monitoring treatment responses, ensuring patients receive timely and efficient care.
The growing prevalence of cancer in India amplifies the importance of these End User segments, as early detection and effective treatment are critical for improving patient outcomes. Overall, the segmentation within the India Cancer Immunotherapy Market highlights the interdependence of these sectors, each contributing to a more robust healthcare framework in addressing cancer treatment and management.
The Route of Administration segment within the India Cancer Immunotherapy Market holds significant importance as it determines the effectiveness and convenience of treatment administration. The segment primarily comprises methods like Intravenous, Subcutaneous, and Intramuscular routes, each with distinct advantages tailored to patient needs.
Intravenous administration is often favored for its rapid delivery into the bloodstream, making it suitable for complex therapies that require immediate therapeutic effects. Conversely, the Subcutaneous route, noted for its ease of administration, has gained traction due to its potential for at-home delivery, enhancing patient compliance, especially among those requiring ongoing treatment.
Meanwhile, Intramuscular injections are utilized for specific formulations, offering benefits in terms of dosing consistency. As India sees a rising cancer incidence, coupled with advancements in immunotherapy techniques, these administration methods are crucial for optimizing therapeutic outcomes, supporting the overall growth trajectory of the India Cancer Immunotherapy Market.
The increasing preference for personalized medicine and targeted therapies further emphasizes the need for diverse routes of administration to cater to various patient profiles and treatment needs.
The India Cancer Immunotherapy Market has emerged as a dynamic and rapidly evolving segment of the healthcare industry, driven by a surge in cancer cases and an increasing emphasis on personalized treatment approaches. The competitive landscape of this market is characterized by a mix of established pharmaceutical companies, innovative biotechnology firms, and a growing number of start-ups dedicated to developing breakthrough therapies.
With significant investments in research and development, these players are poised to harness the potential of immunotherapy to not only enhance treatment efficacy but also improve the overall quality of life for patients suffering from various types of cancer. The market is also seeing collaborations and partnerships aimed at accelerating product development and expanding market reach, which highlights the intense competition among companies striving to establish their presence and reputation in this vital therapeutic area.
Merck & Co has a prominent foothold in the India Cancer Immunotherapy Market, particularly known for its innovative approaches to cancer treatment. The company has successfully launched several immunotherapy products approved for the Indian market, focusing on enhancing the immune system's ability to fight cancer cells.
Merck & Co’s strengths lie in its robust research capabilities and a strong pipeline of clinical trials aimed at expanding the indications for its immunotherapy treatments. The company is also recognized for its extensive marketing and distribution network that allows for widespread access to its therapies across the country.
This strategic positioning, coupled with a commitment to patient education and support programs, enables Merck & Co to maintain a competitive edge and foster relationships with healthcare professionals and patients within the India Cancer Immunotherapy Market.
Novartis is a significant competitor within the India Cancer Immunotherapy Market, renowned for its focus on providing cutting-edge treatment options tailored to oncology. The company has introduced several key products that have garnered attention for their effectiveness and innovative mechanisms of action.
Novartis’ strengths include a solid research foundation and collaborations with leading scientific institutions that fuel ongoing development in immunotherapy. The company’s presence in India is further bolstered by strategic mergers and acquisitions that enhance its product offerings and market access.
By focusing on targeted therapies and the development of combination treatments, Novartis aims to improve patient outcomes while addressing the healthcare needs specific to the Indian population. Its proactive approach in establishing clinical trial centers and engaging with local healthcare providers is a testament to its commitment to advancing cancer care in India.
In recent months, the India Cancer Immunotherapy Market has seen significant developments. In September 2023, the Indian government announced enhanced funding for cancer research and development initiatives, focusing on immunotherapy as a key area for innovation. Major pharmaceutical companies like Merck and Co., Novartis, and AstraZeneca are actively increasing their Research and Development investments in this sector, acknowledging the growing demand for effective cancer treatments.
Recent growth in market valuation has been driven by new clinical trial results demonstrating the effectiveness of immunotherapy drugs, leading to increased adoption among healthcare providers. Notably, in July 2023, Bristol Myers Squibb launched a new combination therapy targeting multiple cancer types, generating positive responses from the medical community.
Additionally, there have been reports of strategic collaborations among companies, including a partnership between Eli Lilly and Gilead Sciences to develop advanced immunotherapies tailored for Indian patients. The overall market is experiencing robust expansion, encouraged by supportive government policies and an increasing focus on personalized medicine in cancer treatment methodologies.
This progress aligns with India's commitment to enhancing cancer care and improving patient outcomes through innovative therapeutic solutions.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 3.34(USD Billion) |
| MARKET SIZE 2024 | 3.51(USD Billion) |
| MARKET SIZE 2035 | 6.0(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.995% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Merck & Co, Novartis, Eli Lilly, AstraZeneca, Johnson & Johnson, Regeneron Pharmaceuticals, Celgene, Roche, BristolMyers Squibb, Amgen, GSK, Sanofi, Takeda Pharmaceutical, Gilead Sciences, Pfizer |
| SEGMENTS COVERED | Therapy Type, Cancer Type, End User, Route of Administration |
| KEY MARKET OPPORTUNITIES | Increased R&D investment, Growing patient awareness, Expanding healthcare infrastructure, Rising incidence of cancer, Government support for innovations |
| KEY MARKET DYNAMICS | Increasing cancer prevalence, Rising government support, Advancements in research, Growing awareness among patients, High investment in biotech firms |
| COUNTRIES COVERED | India |
Frequently Asked Questions (FAQ) :
The India Cancer Immunotherapy Market is projected to be valued at 3.51 USD Billion in 2024.
The India Cancer Immunotherapy Market is expected to grow at a CAGR of 4.995% from 2025 to 2035.
By 2035, the India Cancer Immunotherapy Market is expected to reach a valuation of 6.0 USD Billion.
Monoclonal Antibodies is expected to hold the largest market share, valued at 1.2 USD Billion in 2024.
Key players include Merck & Co, Novartis, Eli Lilly, AstraZeneca, and Johnson & Johnson among others.
The Check Point Inhibitors segment is projected to be valued at 2.3 USD Billion in 2035.
Key trends include advancements in targeted therapies and increased focus on personalized medicine.
The Therapeutic T-Cells segment is valued at 0.5 USD Billion in 2024 and expected to reach 0.9 USD Billion by 2035.
Current global events impact the market by influencing research funding and collaborative opportunities.
In 2024, the Cancer Vaccines segment is projected to be valued at 0.4 USD Billion.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
